FDA Grants Emergency Use Authorization To Eli Lilly’s Monoclonal Antibody For Treatment Of COVID-19

Washington Post: FDA authorizes Eli Lilly antibody drug that Trump touted, but supply will be limited
“The first covid-19 treatment to protect people with mild illness from developing severe disease was granted emergency use authorization by regulators Monday evening. The drug, a laboratory-brewed antibody that imitates the immune system’s attack on the virus, is made by Eli Lilly & Co. Health experts have championed the class of medicine as a powerful tool to change the course of the pandemic and work as a bridge to a vaccine. It is in the same family of medication as an experimental treatment President Trump received when he was stricken with covid-19, the illness the novel coronavirus causes. But the initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic and raise questions about whether it is being distributed to people in the greatest need…” (Johnson, 11/9).

Additional coverage of the drug’s authorization is available from AP, Financial Times, and NBC News.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.